All In Biotech

Drug Trial Radar · NCT07638553

Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 172 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

172

Planned (sponsor's estimate)

Start

Jun 30, 2026

Primary completion

Jun 2030

Study completion Jun 2030

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de NīmesAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 10, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Up to 40% of individuals with alcohol use disorder (AUD) experience depression, which increases the risk of early relapse. Depression can cause relapse to occur 3 times faster in individuals with AUD who experience depressive symptoms at discharge. No treatments have been approved for individuals with both AUD and depression. Psilocybin, a psychedelic, shows promising results in treating both depression and addiction. It may be particularly effective for preventing relapse in people with AUD who also have depressive symptoms after detoxification, offering quicker action than traditional antidepressants. The Psilocybin Alcohol Depression (PAD) pilot study, launched in February 2024, has provided critical insights for avoiding methodological flaws and demonstrated that psilocybin-assisted psychotherapy (PAP) is both feasible and acceptable. Preliminary efficacy analyses were conducted: at 12 weeks, the 25 mg group showed significantly greater reductions in drinking days (p = 0.038) and craving frequency (p = 0.045). Relapse rates were 35% in the 25 mg group and 50% in the control group (HR = 0.52 \[0.16-1.65\]). In the ERPPAD trial, the study authors will compare high-dose PAP with low-dose PAP in preventing relapse in individuals with AUD and depressive symptoms. The hypothesis is that high-dose PAP will be more effective than low-dose in preventing relapse over 6 months.

Conditions

  • Alcohol Use Disorder
  • Depressive Sympotoms
  • Psilocybin

Interventions

  • Psilocybin (high dose)Drug

    2 administrations of high-dose psilocybin (25 mg) 3 weeks apart

  • Psilocybin (low dose)Drug

    2 administrations of low-dose psilocybin (3 mg) 3 weeks apart

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of relapse between groupsTime frame: Month 6
  2. Time to relapse between groupsTime frame: Month 6

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier de la Côte Basque

    Bayonne, France · Not yet recruiting

  • CHU Besançon

    Besançon, France · Not yet recruiting

  • CHU de Bordeaux

    Bordeaux, France · Not yet recruiting

  • CHU Brest

    Brest, France · Not yet recruiting

  • CH Le Vinatier

    Bron, France · Not yet recruiting

  • CHU de Nantes

    Nantes, France · Not yet recruiting

  • CHU de Nîmes

    Nîmes, France · Recruiting

  • CHU Saint-Etienne

    Saint-Priest, France · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.